サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1495387

病院内感染対策市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年

Hospital Acquired Infection Control Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 201 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
病院内感染対策市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年
出版日: 2024年05月11日
発行: Persistence Market Research
ページ情報: 英文 201 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界の病院内感染対策市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題を含む重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主要な洞察

  • 病院内感染対策の市場規模（2024年）：71億3,000万米ドル
  • 予測市場金額（2033年）：101億米ドル
  • 世界市場成長率（CAGR、2024～2033年）：3.9%

病院内感染対策市場 - レポート範囲：

病院内感染（HAI）とは、ヘルスケア環境において患者が内科的または外科的疾患の治療を受けている間に感染することです。HAI対策市場には、尿路感染症、手術部位感染症、肺炎、血流感染症などの感染症の予防、診断、治療を目的とした製品とサービスが含まれます。この市場の主要製品には、滅菌装置、消毒剤、監視システム、診断装置などがあります。HAI対策市場は、病院、診療所、長期ケア施設、診断研究所を対象としています。

市場成長の促進要因：

世界の病院内感染対策市場は、HAIの蔓延、ヘルスケア支出の増加、患者の安全性向上を目的とした厳しい規制など、いくつかの重要な要因によって推進されています。滅菌・消毒技術の進歩は、革新的な診断ツールの開発とともに、感染対策の有効性を高めています。さらに、ヘルスケア専門家や患者の間で感染予防に対する認識や教育が高まっていることも、市場の成長を後押ししています。

市場抑制要因：

有望な成長見通しにもかかわらず、HAI対策市場は、高度な感染対策製品や機器の高額なコスト、規制への対応、ヘルスケアスタッフの継続的なトレーニングの必要性などに関連する課題に直面しています。感染制御製品の製造と使用を規定する厳しい規制は、メーカーとヘルスケアプロバイダーにコンプライアンス負担を課し、市場参入障壁と運営コストに影響を与えます。さらに、特定の感染制御処置に対する償還範囲が限られているため、特に医療予算に制約のある新興国では、市場浸透のための課題となっています。

市場機会：

HAI対策市場は、技術革新、人口動向、進化するヘルスケア提供モデルによって大きな成長機会がもたらされます。リアルタイムの感染監視システムや電子カルテなどのデジタルヘルス技術の統合は、感染制御プログラムの効果を高めます。さらに、低侵襲外科手術の採用拡大や外来患者ケア環境の拡大により、市場関係者には新たな道が開けています。戦略的パートナーシップ、研究開発への投資、費用対効果が高く使いやすい感染制御ソリューションのイントロダクションは、新たな機会を活用し、市場でのリーダーシップを維持するために不可欠です。

本レポートで扱う主要な質問

  • 世界の病院内感染対策市場の成長を促進する主要な要因は何か？
  • さまざまなヘルスケア環境で採用を促進している製品とアプリケーションは何か？
  • 技術の進歩はHAI制御市場の競合情勢をどのように変えているのか？
  • HAIコントロール市場に貢献している主要企業は誰で、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界のHAIコントロール市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品イノベーション / 開発動向

第4章 主要な成功要因

  • 製品の採用 / 使用状況分析
  • 主要マーケティング・プロモーション戦略：メーカー別
  • 規制状況
  • 払い戻しシナリオ
  • 品質監視プログラム
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • 2024年の市場シナリオ
  • COVID-19と影響分析
    • 製品別
    • エンドユーザー別
    • 地域別

第7章 世界の病院内感染対策市場の需要分析

  • 過去の市場分析：2019～2023年
  • 現在および将来の市場予測、2024～2033年
    • 前年比成長動向分析

第8章 世界の病院内感染対策市場 - 価格分析

  • 地域別価格分析：製品別
  • 価格の内訳
    • メーカーレベルの価格設定
    • ディストリビューターレベルの価格設定
  • 世界平均価格分析ベンチマーク
  • 価格設定の前提条件

第9章 世界の病院内感染対策市場の需要分析

  • 過去の市場金額分析：2019～2023年
  • 現在および将来の市場金額予測、2024～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第10章 世界の病院内感染対策市場分析：製品別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模と数量分析：製品別、2019～2023年
  • 現在および将来の市場規模と数量分析と予測：製品別、2024～2033年
    • 加熱殺菌装置
    • 低温殺菌装置
    • 放射線滅菌装置
    • 消毒装置
  • 市場魅力度分析：製品別

第11章 世界の病院内感染対策市場分析：エンドユーザー別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模分析：エンドユーザー別：2019～2023年
  • 現在および将来の市場規模の分析と予測：エンドユーザー別、2024～2033年
    • 病院
    • 外来手術センター
    • 医療機関
    • 診断検査室
    • クリニック
  • 市場魅力度分析：エンドユーザー別

第12章 世界の病院内感染対策市場分析：地域別

  • イントロダクション
  • 過去の市場規模と数量分析：地域別、2019～2023年
  • 現在および将来の市場規模と数量分析と予測：地域別、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第13章 北米の病院内感染対策市場分析

第14章 ラテンアメリカの病院内感染対策市場分析

第15章 欧州の病院内感染対策市場分析

第16章 南アジアの病院内感染対策市場分析

第17章 東アジアの病院内感染対策市場分析

第18章 オセアニアの病院内感染対策市場分析

第19章 中東・アフリカ（MEA）の病院内感染対策市場分析

第20章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細情報
    • Olympus Corporation
    • Medivators Inc.（Cantel Medical Corp.）
    • Getinge Group
    • STERIS Plc.
    • Belimed AG（Metall Zug）
    • Steelco SPA
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck &Co.
    • Advanced Sterilization Products Services Inc.（Johnson &Johnson）
    • Abbott Laboratories
    • Bayer AG
    • Alere Inc.
    • The 3M Company
    • Cepheid Inc.
    • UVision360 Inc.

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP2814

Persistence Market Research has recently released a comprehensive report on the worldwide market for hospital acquired infection control. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Hospital Acquired Infection Control Market Size (2024E): USD 7.13 Billion
  • Projected Market Value (2033F): USD 10.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 3.9%

Hospital Acquired Infection Control Market - Report Scope:

Hospital acquired infections (HAIs) are infections that patients acquire while receiving treatment for medical or surgical conditions in healthcare settings. The market for HAI control includes products and services designed to prevent, diagnose, and treat infections such as urinary tract infections, surgical site infections, pneumonia, and bloodstream infections. Key products in this market include sterilization equipment, disinfectants, surveillance systems, and diagnostic devices. The HAI control market caters to hospitals, clinics, long-term care facilities, and diagnostic laboratories.

Market Growth Drivers:

The global hospital acquired infection control market is propelled by several key factors, including the rising prevalence of HAIs, increasing healthcare expenditures, and stringent regulations aimed at improving patient safety. Advances in sterilization and disinfection technologies, along with the development of innovative diagnostic tools, enhance the efficacy of infection control measures. Additionally, growing awareness and education about infection prevention among healthcare professionals and patients further drive market growth.

Market Restraints:

Despite promising growth prospects, the HAI control market faces challenges related to the high costs of advanced infection control products and equipment, regulatory compliance, and the need for continuous training of healthcare staff. The stringent regulations governing the manufacturing and use of infection control products impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, limited reimbursement coverage for certain infection control procedures poses challenges for market penetration, particularly in emerging economies with constrained healthcare budgets.

Market Opportunities:

The HAI control market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as real-time infection surveillance systems and electronic health records, enhances the effectiveness of infection control programs. Additionally, the increasing adoption of minimally invasive surgical procedures and the expansion of outpatient care settings create new avenues for market players. Strategic partnerships, investment in research and development, and the introduction of cost-effective, user-friendly infection control solutions are essential to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the hospital acquired infection control market globally?
  • Which products and applications are driving adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the HAI control market?
  • Who are the key players contributing to the HAI control market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global HAI control market?

Competitive Intelligence and Business Strategy:

Leading players in the global hospital acquired infection control market, including 3M Company, Johnson & Johnson, and Becton, Dickinson and Company, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced infection control solutions, such as automated sterilization systems, advanced disinfectants, and rapid diagnostic tests, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving infection control landscape.

Key Companies Profiled:

  • Olympus Corporation
  • Medivators Inc. (Cantel Medical Corp.)
  • Getinge Group
  • STERIS Plc.
  • Belimed AG (Metall Zug)
  • Steelco S.P.A
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co.
  • Advanced Sterilization Products Services Inc. (Johnson & Johnson)
  • Abbott Laboratories
  • Bayer AG
  • Alere Inc.
  • The 3M Company
  • Cepheid Inc
  • UVision360 Inc.

Key Segments of the Hospital Acquired Infection Control Market

By Product :

  • Heat Sterilization Equipment
  • Low-Temperature Sterilization Equipment
  • Radiation Sterilization Equipment
  • Disinfection Equipment

By End User :

  • Hospitals
  • Ambulatory Surgical Centres
  • Medical Institutions
  • Diagnostic Laboratories
  • Clinics

By Region :

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Key Marketing & Promotion Strategies, By Manufacturers
  • 4.3. Regulatory Landscape
  • 4.4. Reimbursement Scenario.
  • 4.5. Quality Monitoring Programs
  • 4.6. PESTEL Analysis
  • 4.7. Porter's Analysis.

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Industry Outlook
    • 5.1.3. Hospital Acquired Infection Market Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Focus on Personal Hygiene
    • 5.2.2. Increasing Prevalence of Infectious Diseases
    • 5.2.3. New Product Launch Activities
    • 5.2.4. Technological Advancements
    • 5.2.5. Increasing Minimally Invasive Procedures
    • 5.2.6. Susceptible Patients and Surgical Procedures
    • 5.2.7. Co-Existing Infections
    • 5.2.8. Increased Funding and Support from the Government
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. 2024 Market Scenario
  • 6.2. COVID-19 and Impact Analysis
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Region

7. Global Hospital Acquired Infection Control Market Demand (in Volume) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market (Volume) Analysis, 2019-2023
  • 7.2. Current and Future Market (Volume) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis

8. Global Hospital Acquired Infection Control Market - Pricing Analysis

  • 8.1. Regional Pricing Analysis, By Product
  • 8.2. Pricing Break-up
    • 8.2.1. Manufacturer Level Pricing
    • 8.2.2. Distributor Level Pricing
  • 8.3. Global Average Pricing Analysis Benchmark
  • 8.4. Pricing Assumptions

9. Global Hospital Acquired Infection Control Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 9.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 9.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 9.2.1. Y-o-Y Growth Trend Analysis
    • 9.2.2. Absolute $ Opportunity Analysis

10. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Product, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2033
    • 10.3.1. Heat Sterilization Equipment
      • 10.3.1.1. Moist Heat Sterilization Equipment
      • 10.3.1.2. Dry Heat Sterilization Equipment
    • 10.3.2. Low Temperature Sterilization Equipment
    • 10.3.3. Radiation Sterilization Equipment
    • 10.3.4. Disinfection Equipment
      • 10.3.4.1. Disinfector
        • 10.3.4.1.1. Washer Disinfector
        • 10.3.4.1.2. Flusher Disinfector
      • 10.3.4.2. Endoscopic Reprocessor Systems
        • 10.3.4.2.1. Single Basin Endoscopic Reprocessor Systems
        • 10.3.4.2.2. Dual Basin Endoscopic Reprocessor Systems
      • 10.3.4.3. Disinfectants
  • 10.4. Market Attractiveness Analysis, By Product

11. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By End User

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2033
    • 11.3.1. Hospitals
    • 11.3.2. Ambulatory Surgical Centers
    • 11.3.3. Medical Institutions
    • 11.3.4. Diagnostic Laboratories
    • 11.3.5. Clinics
  • 11.4. Market Attractiveness Analysis, By End User

12. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis by Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis, By Region

13. North America Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Product
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By End User
  • 13.5. Key Market Participants - Intensity Mapping
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Market Trends
  • 13.8. Country-Level Analysis & Forecast
    • 13.8.1. U.S. Hospital Acquired Infection Control Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By End User
    • 13.8.2. Canada Hospital Acquired Infection Control Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By End User

14. Latin America Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Product
    • 14.3.3. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By End User
  • 14.5. Key Market Participants - Intensity Mapping
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Market Trends
  • 14.8. Country-Level Analysis & Forecast
    • 14.8.1. Mexico Hospital Acquired Infection Control Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By End User
    • 14.8.2. Brazil Surgical Imaging Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By End User
    • 14.8.3. Argentina Hospital Acquired Infection Control Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By End User

15. Europe Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. U.K.
      • 15.3.1.2. Germany
      • 15.3.1.3. Italy
      • 15.3.1.4. France
      • 15.3.1.5. Spain
      • 15.3.1.6. Russia
      • 15.3.1.7. BENELUX
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Product
    • 15.3.3. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By End User
  • 15.5. Key Market Participants - Intensity Mapping
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Market Trends
  • 15.8. Country-Level Analysis & Forecast
    • 15.8.1. U.K. Hospital Acquired Infection Control Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By End User
    • 15.8.2. Germany Hospital Acquired Infection Control Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By End User
    • 15.8.3. Italy Hospital Acquired Infection Control Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By End User
    • 15.8.4. France Hospital Acquired Infection Control Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By End User
    • 15.8.5. Spain Hospital Acquired Infection Control Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By End User
    • 15.8.6. Russia Hospital Acquired Infection Control Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By End User
    • 15.8.7. BENULUX Hospital Acquired Infection Control Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By End User

16. South Asia Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Product
    • 16.3.3. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By End User
  • 16.5. Key Market Participants - Intensity Mapping
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Market Trends
  • 16.8. Country-Level Analysis & Forecast
    • 16.8.1. India Hospital Acquired Infection Control Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By End User
    • 16.8.2. Indonesia Hospital Acquired Infection Control Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By End User
    • 16.8.3. Malaysia Hospital Acquired Infection Control Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By End User
    • 16.8.4. Thailand Hospital Acquired Infection Control Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By End User

17. East Asia Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Product
    • 17.3.3. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By End User
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Market Trends
  • 17.8. Country-Level Analysis & Forecast
    • 17.8.1. China Hospital Acquired Infection Control Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By End User
    • 17.8.2. Japan Hospital Acquired Infection Control Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By End User
    • 17.8.3. South Korea Hospital Acquired Infection Control Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By End User

18. Oceania Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Product
    • 18.3.3. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By End User
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Market Trends
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Hospital Acquired Infection Control Market
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Product
        • 18.8.1.2.2. By End User
    • 18.8.2. New Zealand Hospital Acquired Infection Control Market
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Product
        • 18.8.2.2.2. By End User

19. Middle East and Africa (MEA) Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Product
    • 19.3.3. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Product
    • 19.4.3. By End User
  • 19.5. Key Market Participants - Intensity Mapping
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Market Trends
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Hospital Acquired Infection Control Market
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Product
        • 19.8.1.2.2. By End User
    • 19.8.2. Turkey Hospital Acquired Infection Control Market
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Product
        • 19.8.2.2.2. By End User
    • 19.8.3. South Africa Hospital Acquired Infection Control Market
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Product
        • 19.8.3.2.2. By End User
    • 19.8.4. North Africa Hospital Acquired Infection Control Market
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Product
        • 19.8.4.2.2. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional footprint of Players
    • 20.3.2. Product foot print by Players
    • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Olympus Corporation
      • 21.3.1.1. Company Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financials
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Key Developments
      • 21.3.1.7. Strategy Overview
        • 21.3.1.7.1. Marketing Strategy
        • 21.3.1.7.2. Product Strategy
        • 21.3.1.7.3. Channel Strategy
    • 21.3.2. Medivators Inc. (Cantel Medical Corp.)
      • 21.3.2.1. Company Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financials
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Key Developments
      • 21.3.2.7. Strategy Overview
        • 21.3.2.7.1. Marketing Strategy
        • 21.3.2.7.2. Product Strategy
        • 21.3.2.7.3. Channel Strategy
    • 21.3.3. Getinge Group
      • 21.3.3.1. Company Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financials
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Key Developments
      • 21.3.3.7. Strategy Overview
        • 21.3.3.7.1. Marketing Strategy
        • 21.3.3.7.2. Product Strategy
        • 21.3.3.7.3. Channel Strategy
    • 21.3.4. STERIS Plc.
      • 21.3.4.1. Company Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financials
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Key Developments
      • 21.3.4.7. Strategy Overview
        • 21.3.4.7.1. Marketing Strategy
        • 21.3.4.7.2. Product Strategy
        • 21.3.4.7.3. Channel Strategy
    • 21.3.5. Belimed AG (Metall Zug)
      • 21.3.5.1. Company Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financials
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Key Developments
      • 21.3.5.7. Strategy Overview
        • 21.3.5.7.1. Marketing Strategy
        • 21.3.5.7.2. Product Strategy
        • 21.3.5.7.3. Channel Strategy
    • 21.3.6. Steelco S.P.A
      • 21.3.6.1. Company Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financials
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Key Developments
      • 21.3.6.7. Strategy Overview
        • 21.3.6.7.1. Marketing Strategy
        • 21.3.6.7.2. Product Strategy
        • 21.3.6.7.3. Channel Strategy
    • 21.3.7. Pfizer Inc.
      • 21.3.7.1. Company Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financials
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Key Developments
      • 21.3.7.7. Strategy Overview
        • 21.3.7.7.1. Marketing Strategy
        • 21.3.7.7.2. Product Strategy
        • 21.3.7.7.3. Channel Strategy
    • 21.3.8. F. Hoffmann-La Roche Ltd
      • 21.3.8.1. Company Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financials
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Key Developments
      • 21.3.8.7. Strategy Overview
        • 21.3.8.7.1. Marketing Strategy
        • 21.3.8.7.2. Product Strategy
        • 21.3.8.7.3. Channel Strategy
    • 21.3.9. Merck & Co.
      • 21.3.9.1. Company Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financials
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Key Developments
      • 21.3.9.7. Strategy Overview
        • 21.3.9.7.1. Marketing Strategy
        • 21.3.9.7.2. Product Strategy
        • 21.3.9.7.3. Channel Strategy
    • 21.3.10. Advanced Sterilization Products Services Inc. (Johnson & Johnson)
      • 21.3.10.1. Company Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financials
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Key Developments
      • 21.3.10.7. Strategy Overview
        • 21.3.10.7.1. Marketing Strategy
        • 21.3.10.7.2. Product Strategy
        • 21.3.10.7.3. Channel Strategy
    • 21.3.11. Abbott Laboratories
      • 21.3.11.1. Company Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financials
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Key Developments
      • 21.3.11.7. Strategy Overview
        • 21.3.11.7.1. Marketing Strategy
        • 21.3.11.7.2. Product Strategy
        • 21.3.11.7.3. Channel Strategy
    • 21.3.12. Bayer AG
      • 21.3.12.1. Company Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financials
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Key Developments
      • 21.3.12.7. Strategy Overview
        • 21.3.12.7.1. Marketing Strategy
        • 21.3.12.7.2. Product Strategy
        • 21.3.12.7.3. Channel Strategy
    • 21.3.13. Alere Inc.
      • 21.3.13.1. Company Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financials
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Key Developments
      • 21.3.13.7. Strategy Overview
        • 21.3.13.7.1. Marketing Strategy
        • 21.3.13.7.2. Product Strategy
        • 21.3.13.7.3. Channel Strategy
    • 21.3.14. The 3M Company
      • 21.3.14.1. Company Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financials
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Key Developments
      • 21.3.14.7. Strategy Overview
        • 21.3.14.7.1. Marketing Strategy
        • 21.3.14.7.2. Product Strategy
        • 21.3.14.7.3. Channel Strategy
    • 21.3.15. Cepheid Inc.
      • 21.3.15.1. Company Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Sales Footprint
      • 21.3.15.4. Key Financials
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Key Developments
      • 21.3.15.7. Strategy Overview
        • 21.3.15.7.1. Marketing Strategy
        • 21.3.15.7.2. Product Strategy
        • 21.3.15.7.3. Channel Strategy
    • 21.3.16. UVision360 Inc.
      • 21.3.16.1. Company Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Sales Footprint
      • 21.3.16.4. Key Financials
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Key Developments
      • 21.3.16.7. Strategy Overview
        • 21.3.16.7.1. Marketing Strategy
        • 21.3.16.7.2. Product Strategy
        • 21.3.16.7.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology